PMID- 21303373
OWN - NLM
STAT- MEDLINE
DCOM- 20110919
LR  - 20110708
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 51
IP  - 7
DP  - 2011 Jul
TI  - Nonleukemic myeloid dendritic cells obtained from autologous stem cell products 
      elicit antileukemia responses in patients with acute myeloid leukemia.
PG  - 1546-55
LID - 10.1111/j.1537-2995.2010.03042.x [doi]
AB  - BACKGROUND: Dendritic cell (DC)-based immunotherapeutic protocols are being 
      developed to treat acute myeloid leukemia (AML). So far, DCs for clinical use are 
      obtained from leukemic blasts or from monocytes, after 6 to 10 days of ex vivo 
      culture. However, DC precursors are easily driven to DCs in short-term culture. 
      We tested if DC precursors contained in peripheral blood stem cell (PBSC) 
      products obtained from AML patients can be used to induce antileukemia responses. 
      STUDY DESIGN AND METHODS: PBSCs obtained from 30 consecutive AML patients were 
      tested. Myeloid DCs (MDCs) were purified by immunomagnetic selection and screened 
      for cytogenetic and/or molecular abnormalities by fluorescence in situ 
      hybridization (FISH) or polymerase chain reaction (PCR) assays. MDCs were matured 
      and pulsed with autologous blast lysates and tested for stimulatory capability 
      against AML cells. RESULTS: A median of 0.62 x 10(6) MDCs (range, 0.04-3.25)/mL 
      were quantified in PBSC products. Isolated MDC expressed Class I and II HLA but 
      CD86, CD54, and CCR5 partially. By FISH or PCR assay, these MDCs lacked 
      cytogenetic or molecular abnormalities detected in leukemia cells at diagnosis. 
      MDCs achieved a maturated stage (mature-MDCs) after 24-hour ex vivo culture with 
      tumor necrosis factor-alpha and autologous blast lysates. These mature-MDCs were 
      capable of stimulating autologous peripheral blood effectors to exert 
      cytotoxicity against autologous leukemia cells and HL-60 cell line. CONCLUSION: 
      We conclude that PBSCs obtained for autologous stem cell transplantation can 
      constitute a novel source of MDCs to design feasible vaccination trials.
CI  - (c) 2011 American Association of Blood Banks.
FAU - Serrano-Lopez, Juana
AU  - Serrano-Lopez J
AD  - Department of Hematology and Laboratory for Cellular Therapy, Instituto 
      Maimonides Investigacion Biomedica, Cordoba, Spain.
FAU - Sanchez-Garcia, Joaquin
AU  - Sanchez-Garcia J
FAU - Serrano, Josefina
AU  - Serrano J
FAU - Alvarez-Rivas, Miguel A
AU  - Alvarez-Rivas MA
FAU - Garcia-Castellano, Jose M
AU  - Garcia-Castellano JM
FAU - Roman-Gomez, Jose
AU  - Roman-Gomez J
FAU - de la Rosa, Olga
AU  - de la Rosa O
FAU - Herrera-Arroyo, Concepcion
AU  - Herrera-Arroyo C
FAU - Torres-Gomez, Antonio
AU  - Torres-Gomez A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110208
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
SB  - IM
MH  - Cell Culture Techniques
MH  - Dendritic Cells/*immunology/*transplantation
MH  - Feasibility Studies
MH  - Graft vs Leukemia Effect/*immunology
MH  - Humans
MH  - Immunomagnetic Separation
MH  - Immunotherapy
MH  - Leukemia, Myeloid, Acute/immunology/*therapy
MH  - Peripheral Blood Stem Cell Transplantation
MH  - Time Factors
MH  - Transplantation, Autologous
MH  - Tumor Cells, Cultured
EDAT- 2011/02/10 06:00
MHDA- 2011/09/20 06:00
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/09/20 06:00 [medline]
AID - 10.1111/j.1537-2995.2010.03042.x [doi]
PST - ppublish
SO  - Transfusion. 2011 Jul;51(7):1546-55. doi: 10.1111/j.1537-2995.2010.03042.x. Epub 
      2011 Feb 8.